Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX), Theravance Biopharma (NASDAQ: TBPH) and Magenta Therapeutics (NASDAQ: MGTA)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pacira Pharmaceuticals (PCRXResearch Report), Theravance Biopharma (TBPHResearch Report) and Magenta Therapeutics (MGTAResearch Report).

Pacira Pharmaceuticals (PCRX)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Pacira Pharmaceuticals today and set a price target of $93.00. The company’s shares closed last Wednesday at $55.51.

According to TipRanks.com, Moussatos is a 3-star analyst with an average return of 5.9% and a 41.2% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Eiger Biopharmaceuticals, and BioMarin Pharmaceutical.

Currently, the analyst consensus on Pacira Pharmaceuticals is a Strong Buy with an average price target of $83.00, representing a 51.6% upside. In a report released today, Needham also maintained a Buy rating on the stock with a $80.00 price target.

See today’s analyst top recommended stocks >>

Theravance Biopharma (TBPH)

In a report released today, Joseph Stringer from Needham downgraded Theravance Biopharma to Hold. The company’s shares closed last Wednesday at $6.90.

According to TipRanks.com, Stringer is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.1% and a 29.4% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Lexicon Pharmaceuticals, and Phathom Pharmaceuticals.

Currently, the analyst consensus on Theravance Biopharma is a Hold with an average price target of $17.38.

Magenta Therapeutics (MGTA)

In a report released today, Kalpit Patel from B.Riley Financial maintained a Buy rating on Magenta Therapeutics, with a price target of $19.00. The company’s shares closed last Wednesday at $6.66, close to its 52-week low of $5.89.

According to TipRanks.com, Patel is a 1-star analyst with an average return of -8.9% and a 26.7% success rate. Patel covers the Healthcare sector, focusing on stocks such as Allogene Therapeutics, Forte Biosciences, and Infinity Pharma.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Magenta Therapeutics with a $15.71 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.